Accord BioPharma's IMULDOSA® Covered by Cigna Healthcare Starting April 15, 2026
Accord BioPharma's biosimilar IMULDOSA® (ustekinumab-srlf) has been added to Cigna Healthcare's commercial plans, effective April 15, 2026. The drug, approved in October 2024, is now preferred on both pharmacy and medical benefits, improving patient access to the treatment. This development is seen as a positive step for Accord in the U.S. biosimilar market.
Tickers: $CI
Topics: biosimilar formulary status healthcare access pharmaceutical coverage